drugset / Trial / NCT01405963

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

NCT01405963

Phase 1 Completed 31 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety, tolerability, immunogenicity, and pharmacokinetics of multiple doses of tezepelumab in adults with mild atopic asthma.

Timeline

Start
2011-10-31
Primary completion
2013-04-05
Completion
2013-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tezepelumab Monoclonal antibody 700 mg Intravenous

Indications